State of Alaska Department of Revenue’s Fulcrum Therapeutics FULC Stock Holding History

State of Alaska Department of Revenue’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113K	Buy	+31,000	New	+$189K	﹤0.01%	1747

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

State of Alaska Department of Revenue's FULC Position: Q2 2026 in Review

State of Alaska Department of Revenue opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 31,000 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #1747 among its holdings.

71 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

State of Alaska Department of Revenue held 31,000 shares of Fulcrum Therapeutics worth $113K as of Q2 2026.
Fulcrum Therapeutics was a new State of Alaska Department of Revenue position in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1747 holding.
71 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.